Prophylix Pharma is a Norwegian biotech company developing orphan drugs for the prevention of life-threatening or chronically disabling intracranial bleeding in fetuses due to fetal and neonatal alloimmune thrombocytopenia (FNAIT). The lead drug NAITgam contains specific IgG antibodies derived from plasma of women with a history of FNAIT in their fetus or newborn. The NAITgam is developed within the frames of the EU-supported PROFNAIT project, read more at: www.profnait.eu
Prophylix Pharma is a Norwegian biotech company developing orphan drugs for the prevention of life-threatening or chronically disabling intracranial bleeding in fetuses due to fetal and neonatal alloimmune thrombocytopenia (FNAIT). The lead drug NAITgam contains specific IgG antibodies derived from plasma of women with a history of FNAIT in their fetus or newborn. The NAITgam is developed within the frames of the EU-supported PROFNAIT project, read more at: www.profnait.eu
Company Information
- Industry
- Biotechnology
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- Forskningsparken Tromsø
- City
- Region
- Postal Code
- Country
- Greenland